Eculizumab
Summary
Eculizumab is a recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
Generic Name: Eculizumab
Background
Eculizumab is a monoclonal antibody that targets complement protein C5.7,1 Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.7,1,2
Eculizumab was granted FDA approval on 16 March 2007.7
Protein Chemical Formula: Not Available
Protein Average Weight: 148000.0 Da